Axsome Therapeutics’ AXS-05 challenges current standard of care as promising non-antipsychotic for… EP News Bureau Apr 10, 2025 AXS-05 emerges as a potential first-in-class, non-antipsychotic treatment for Alzheimer’s agitation, positioning Axsome…
IA-2A positivity could help develop effective intervention strategies in type 1 diabetes… EP News Bureau Mar 13, 2025 IA-2A identified as a key biomarker for type 1 diabetes risk stratification and early intervention strategies
DREAM-HF trial results highlight Mesoblast’s potential to differentiate in HF space: GlobalData EP News Bureau Dec 19, 2024 Revascor shows potential in reducing cardiovascular mortality and improving outcomes in high-risk heart failure patients, marking…
